This interview, from May, 2004, contains a frank discussion of what went wrong with COR’s initial Ampakine compound, CX-516, and why the follow-on molecule, CX-717, should work a heck of a lot better. A pretty good overview of this promising --and exceptionally cheap-- company in the CNS arena.
It’s instructive to compare this TWST interview with one from last summer (#msg-3202870) to see just what has changed in the ensuing ten months.
Market Data 
Markets 
AI
